CONVALENCE PLASMA THERAPY GUIDELINES

The infection with the SARS-CoV-2 virus, which was first discovered in Wuhan, China, has been shown to cause a person to fall into the COVID-19 disease whose clinical manifestations mainly occur in the respiratory tract. Until now, neither medication nor adequate vaccination has been proven effective in dealing with COVID-19. Although the mortality rate shown is generally low, the risk of mortality will increase in patients with special comorbidities such as old age or the presence of comorbidities.

A person's inability to produce adequate immunity is one of the main problems in severe and critical COVID-19 patients. This causes respiratory failure which can lead to death. In this regard, the treatment of Convalescent Plasma Therapy (TPK) has been approved by WHO as one of the COVID-19 treatments. The description of this Convalescent Plasma Therapy (TPK) handbook is sourced from the Protap for the Management of Convalescent Plasma Therapy for COVID-19 Patients compiled by the Indonesian COVID-19 TPK TIM which is adapted to public health conditions against the threat of COVID-19 on the Island of the Gods.